Rheumatology Associates, 8144 Walnut Hill Lane, Dallas, TX 75231, USA.
Rheum Dis Clin North Am. 2012 Nov;38(4):681-705. doi: 10.1016/j.rdc.2012.09.001.
Bisphosphonates are antiresorptive medications widely prescribed for treating osteoporosis. In placebo-controlled clinical trials they have been shown to significantly reduce the risk of osteoporotic fractures. However, reports of atypical femoral fractures and osteonecrosis of the jaw have emerged with long-term use, raising questions regarding their long-term safety. Additionally, questions have also emerged regarding the association between bisphosphonates and other rare adverse events, such as esophageal cancer and atrial fibrillation. This article summarizes the current knowledge regarding the major side effects associated with the use of bisphosphonates, identifies at-risk populations for these side effects, and provides guidance for their use.
双膦酸盐类药物是一种广泛用于治疗骨质疏松症的抗吸收药物。在安慰剂对照临床试验中,它们已被证明可显著降低骨质疏松性骨折的风险。然而,长期使用后出现了非典型股骨骨折和颌骨骨坏死的报告,这引发了对其长期安全性的质疑。此外,关于双膦酸盐类药物与其他罕见不良事件(如食管癌和心房颤动)之间的关联也出现了疑问。本文总结了与使用双膦酸盐类药物相关的主要副作用的现有知识,确定了这些副作用的高危人群,并为其使用提供了指导。